Effects of Empagliflozin on Left Ventricular Remodeling in Patients with Type 2 Diabetes and Coronary Artery Disease: Echocardiographic Substudy of the EMPA-HEART CardioLink-6 Randomized Clinical Trial

Recent clinical trials have demonstrated significant reductions in heart failure hospitalization and cardiovascular death with sodium-glucose cotransport protein 2 inhibitors in patients with or without type 2 diabetes mellitus.1-3 The mechanism of cardiovascular benefit with sodium-glucose transport coprotein 2 inhibitors was investigated in the EMPA-HEART CardioLink-6 trial, a double-blind, placebo-controlled clinical trial that randomized patients with type 2 diabetes and stable coronary artery disease to empagliflozin 10  mg once daily (n = 49) or placebo (n = 48).
Source: Journal of the American Society of Echocardiography - Category: Cardiology Authors: Tags: Letters to the Editor Source Type: research